FI96919B - Veteen liukenemattomia polypeptidejä - Google Patents
Veteen liukenemattomia polypeptidejä Download PDFInfo
- Publication number
- FI96919B FI96919B FI884297A FI884297A FI96919B FI 96919 B FI96919 B FI 96919B FI 884297 A FI884297 A FI 884297A FI 884297 A FI884297 A FI 884297A FI 96919 B FI96919 B FI 96919B
- Authority
- FI
- Finland
- Prior art keywords
- water
- salt
- peptide
- insoluble
- pamoate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Description
96919
VETEEN LIUKENEMATTOMIA POLYPEPTIDEJÄ I VATTEN OLÖSLIGA POLYPEPTIDER
Tämän keksinnön kohteena on patenttivaatimuksen 1 johdanto-osan mukainen menetelmä farmaseuttisesti hyväksyttävän koostumuksen valmistamiseksi. Keksintö koskee terapeuttisesti aktiivisten, mutta veteen liukenemattomien polypepti-dien farmaseuttisia koostumuksia, jotka aikaan saavat peptidien jatkuvan, kontrolloidun ja pitkittyneen vapautumisen fysiologis-tyyppisessä ympäristössä. Keksinnölle on edelleen luonteenomaista, että käytetään elimistössä hajoavia ja elimistöön soveltuvia polymeerejä ja kopolymeerejä alustana, johon veteen liukenemattomat polypeptidit dispergoi-daan tai kapseloidaan.
Tarve saada aikaan peptidien pitkittynyttä vapautumista parenteraalisessa antotavassa on tunnettu jo pitkään (vrt. T.M.S. Chang "Biodegradable semipermeable Microcapsule : " containing enzymes, hormones, vaccines and other biologi-V · cals" lehdessä J. Bioengineering 1, 25 (1976); R. Langer . '.j "Controlled Release of Macromolecules" lehdessä Chemtech, ·; helmikuu 1982, sivut 98-105; F.G. Hutchinson ja B.J.A. Furr • · « 4 "Biodegradable carriers for sustained release of polypepti- • · des" lehdessä TIBTECH, huhtikuu 1987 (voi. 5) sivut 102-106. Alan tunnettua tekniikkaa on lisäksi kuvattu EPS . . 0052510:ssa "Microencapsulation of water soluable polypep- tides", joka on julkaistu 27.08.86 ja EPS 0058481:ssa "Con- • · · tinuous release pharmaceutical compositions", joka on jul- :‘v kaistu 01.10.86.
• « 2 96919 vesiliuokseen huoneen tai ruumiin lämpötilassa ja jotka kuitenkin saavat aikaan tällaisten peptidien tehokkaan ja kontrolloidun vapautumisen, kun niiden yhdistelmiä annetaan pa-renteraalisesti fysiologisessa, pääasiassa vesiperäisessä ympäristössä.
Tämän keksinnön uusi ja yllättävä seuraus on, että polypep-tidit, jotka normaalisti ovat veteen liukenevia luonnossa tai kun ne on valmistettu synteesillä, voidaan edullisesti tehdä veteen liukenemattomiksi muodostamalla liukenemattomia uusia suoloja, kuten pamoichapon, parkkihapon, steariiniha-pon ja muiden ei toksisten veteen liukenemattomien happojen kanssa, ennen niiden mikrokapselointia tai dispersiota elimistössä hajoavaan polymeeriseen alustaan.
Heikonlaisesti liukenevien tai veteen liukenemattomien johdannaisten käyttö on tietysti hyvin tunnettua, jopa peptidi-alalla (Us Patent 4,010,125, palsta 7, rivi 25), kun hitaasti ainetta vapauttavia depot-annostelumuotoJa tarvitaan.
Kuitenkin kun elimistössä hajoavia polymeerejä, kuten poly-maitohappoa, polyglykolihappoa, polyhydroksivoihappoa, poly-ortho-estereitä, polyasetaaleja ja vastaavia käytetään lääkkeen vapautussysteemeinä, peptidien vapautuminen keskeyty- i l 1 mättömällä tavalla on jatkuvasti vaatinut olennaista veteen liukenevuutta. Raportoidut kokeet ovat osoittaneet, että po- ♦ · · lymeerien (kuten polylaktidin ja polylaktidi-ko-glykolidin ·** * V. esimerkiksi) hajoaminen elimistössä johtaa veden sitomiseen ja sellaisten vesikanavien tai huokosten syntymiseen, joista peptidit vuotavat ulos, koska ne ovat veteen liukenevia.
• · · « · ♦ « · · *·. Keksintömme, että peptidit voivat vapautua aineista ja mik- rokapseleista erittäin tavoitellun vapautumismallin mukaan, • · ·*.* kun niiden veteen liukenevuus vähennetään käytännölisesti katsoen nollatasolle, on yllättävää ja vastoin alan aikai- I « « : sempia opetuksia. Erityisesti havaitsimme, että tiettyjen peptidien, kuten D-Trp®-LHRH:n, vapautuminen polymeerisestä alustasta on parempaa tasaisuuden ja keston suhteen mitä veteen liukenemattomampaa peptidin lisäksi tuleva suola on.
li 3 96919 "Veteen 1 lukeneinattomuus" on täten määritelty peptidin määränä, joka voidaan mitata liuoksessa, kun suolaa dispergoi-daan tai vatkataan tislatussa vedessä 4 tunnin ajan 40°C:n lämpötilassa tai sen alapuolella, määrän ollessa 25 mg/1 tai vähemmän (0-25 ppm).
On erittäin toivottavaa antaa biologisesti aktiivisia polypeptide jä yhtäjaksoisesti ja pitkäkestoisen ajanjakson, yhdestä viikosta useisiin kuukausiin aikana. On myös erittäin toivottavaa, että vapautumiskaava on kontrolloitu, jotta vältetään peptidien epätasaiset vapautumiset terapeuttisen jakson alussa, keskivaiheilla tai lopussa. On usein havaittu, että peptidit vapautuvat elimistössä hajoavista aineista purkauksina (kutsutaan myös purkausvaikutuksiksi), joko kierron alussa tai lopussa, kun polymeerinen aine on hydro-lyysin syövyttämä.
Tämän keksinnön tärkeä piirre on vapautumiskaavan kontrollointi ja yleensä alkupurkauksen väheneminen. Veteen liukenematon peptidi vapautuu vähemmässä määrin kuin sen veteen liukenevat johdannaiset, tuottaen täten pidemmän vapautumis-,'!’« ajan ja estäen yliannostuksen antamisen potilaalle. Muutta malla normaalisti veteen liukeneva peptidi veteen liukene- t < · i mattomaksi kykenemme rajoittamaan alkupurkauksen (se on va-Ta‘.' pautuneen peptidin määrä ensimmäisten 24 tunnin aikana) alle 30 %:iin koko annoksesta.
: : : • *
Esimerkki 1 f ~ 1 • I · • t · ·*· • * r V · Viisikymmentä grammaa D,L-laktidin ja glykolidin kopolymee- riä, jossa D,L-laktidin ja glykolidin molaarinen suhde on 50/50 ja keskimääräinen molekyylipaino 50 000, liuotetaan I t ·' 950 grammaan metyleenikloridia.
i t I 1
Liuos suodatetaan millipore-suodattimen läpi tarkoituksena poistaa kaikki partikkelit ja pyrogeenit. Tähän liuokseen lisätään yksi gramma D-Trp® LHRH pamoaattia lisätään tähän 4 96919 liuokseen ja dispergoidaan sekoittajalla.
Tuloksena oleva seos pannaan pyörivään haihduttimeen ja suurin osa metyleenikloridista poistetaan vakuumissa. Näin saatu paksu dispersio kaadetaan lasilevylle ja levitetään 0,7mm:iin säädetyllä terällä.
Ilmassa kuivauksen jälkeen tuloksena olevaa filmiä kuivataan vakuumissa 48 tuntia ja puristetaan sitten paineessa 0,8 mm suuttimen läpi 70°C:n lämpötilassa. Tuloksena olevat sauvat jauhetaan -40°C:n kylmyydessä.
Tuloksena oleva rakeinen aine siivilöidään 180 jm siivilän läpi ja alamittainen fraktio kerätään ja steriloidaan gammasäteilyllä, jonka voimakkuus on 2,5 -2,8 Mrad.
»
: Esimerkki II
« · ·
Noudatetaan samaa menetelmää kuin esimerkissä 1 korvaamalla D-Trp^-LHRH pamoaatti D-TRP^-LHRH stearaattisuolalla.
Esimerkki III
Noudatetaan samaa menetelmää kuin esimerkissä I käyttäen • I __ D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2: n pamoaatti suolaa • · .1 I veteen liukenemattomana peptidinä.
t · · • · · • ·
II
· · · · • · * ·
Esimerkki IV
• · · • · • · • · ·
Esimerkin I menetelmää sovelletaan yhteen seuraavista veteen liukenemattomista pamoaattisuoloista: D-Nal(2)6 LHRH pamoaatti D-Ser(0-tBu)6 -des Gly^^-Azgly^-^-LHRH pamoaatti D-SerCBu^J^LHRHil-g) etyyliamidi pamoaatti D-Leu^-des Gly^-LHRH etyyliamidi pamoaatti 5 96919
Esimerkki V
Esimerkkien I-IV menetelmää noudatetaan käyttäen D,L lakti-di-ko-glykolidipolymeerejä, joissa molaarinen suhde oli 67% D,L laktidia 33% glykolidia, 75% D,L laktidia 25% glykolidia tai 100% D,L laktidia.
Esimerkki VI
Noudatetaan esimerkkien I-V menetelmää käyttäen yhtä seuraa-vien peptidien veteen liukenemattomista pamoaatti-, tannaat-ti- tai stearaattisuoloista: oksitosiini, vasopressiini, ACTH, kalsitoniini, epidermaalinen kasvutekijä, prolaktiini, inhibiini, interferoni, LHRH, somatostatiini, insuliini, glukagoni, sydämen natriureettinen hormomi, endorfiini, reniini-inhibiittori, GHRH, peptidi-T, tai niiden .·. : synteettisiä analogeja ja modifikaatioita.
* « · < · · ;; Vapautumismalli eläimillä (rotilla) • I ·
Implantoidun D-Trp^-LHRH pamoaatin tyypillinen vapautumismalli rotilla on seuraava: ng/ml radioaktiivisesti merkittyä D-Trp^-LHRH plasmassa (kuuden rotan keskiarvo): (t0) 0,04, :V: (1 h) 7,74, (6 h) 0,80, (2 vrk) 0,85, (4vrk) 0,77, (7 vrk) :Y: 0,25, (11 vrk) 0,12, (14 vrk) 0,11, (18 vrk) 0,11, (21 vrk) .·*: 0,14, (25 vrk) 0,18.
• « · • · · ] Edellä olevat esimerkit eivät rajoitu kuvattuihin veteen ·/:*: liukenemattomiin peptideihin tai käytettyihin elimistössä ·’**: hajoaviin peptideihin, kuten on selvää alan asiantuntijalle.
- · · ·
Claims (7)
1. Menetelmä farmaseuttisesti hyväksyttävän koostumuksen valmistamiseksi, joka on suunniteltu pitkittyneelle ja kontrolloidulle peptidi lääkeaineen vapautumiselle pitkän ajanjakson kuluessa, joka koostumus käsittää polyaktidin, polyglykolidin, maitohapon ja glykolihapon kopolymeerin tai sellaisten polymeerien seoksen ja farmaseuttisesti hyväksyttävän veteen liukenemattoman peptidin, tunnettu siitä, että veteen liukenemattoman peptidin suola dispergoidaan polyaktidin, polyglykolidin, maitohapon ja glykolihapon kopolymeerin tai tällaisten polymeerien seosten liuokseen, poistetaan liuotin kuivaamalla ja muotoillaan tuloksena oleva seos kiinteiksi hiukkasiksi, jotka sopivat parenteraaliseen injektioon ja joka asetettuna vesiperäiseen fysiologis-tyyp-piseen ympäristöön vapauttaa peptidiä ainakin viikon pituisen ajanjakson, kuitenkaan vapauttamatta ensimmäisen vuorokauden aikana enempää kuin 30 % vapautumisen kokonaismäärästä.
• · .* 2. Patenttivaatimuksen l mukainen menetelmä, tunnettu siitä, että farmaseuttisesti hyväksyttävä suola on valittu pamoaat- *·· ti-, parkkihappo- ja stearaattisuolan ryhmästä. • · • · · • · ·
3. Patenttivaatimuksen 1 tai 2 mukainen menetelmä, tunnettu siitä, että veteen liukenematon peptidi on farmaseuttisesti . hyväksyttävä LHRH:n tai sen synteettisesti valmistetun • · ♦ *;;·* analogin suola.
• · · • · · :*·.· 4. Patenttivaatimuksen 3 mukainen menetelmä, tunnettu siitä, • · .***. että veteen liukenematon peptidi on D-Trp6-LHRH: n pamoaat- •. tisuola.
5. Patenttivaatimuksen 1 tai 2 mukainen menetelmä, tunnettu siitä, että liukenematon peptidi on farmaseuttisesti hyväksyttävä oksitosiinin, vasopressiinin, ACTH:n, kalsitoniinin, II 96919 epidermaalisen kasvutekijän, prolaktiinin, inhibiinin, interferonin, somatostatiinin, insuliinin, glukagonin, sydämen natriureettisen hormonin, endorfiinin, reniini-inhibiittorin, kasvuhormonia vapauttavan hormonin, peptidi T:n ja niiden synteettisten analogien ja modifikaatioiden suola.
6. Patenttivaatimuksen 5 mukainen menetelmä, tunnettu siitä, että veteen liukenematon peptidi on D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2: n pamoaattisuola.
7. Jonkin patenttivaatimuksista 1-6 mukainen menetelmä, tunnettu siitä, että koostumus on injektoitavassa muodossa ja että partikkelit vaihtelevat kooltaan 1 /xm:stä 500 Mm:iin. • · • t • « « • « · » · • « · • · • · · « · • · • · · • · · • · • · · • 1 2 3 t • · · • · · • · · • « · ♦ • · ♦ • · · 2 • · 3 • · • · • · · • » 1 ♦ ♦ • ♦ • φ β 96919
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8722134 | 1987-09-21 | ||
GB8722134A GB2209937B (en) | 1987-09-21 | 1987-09-21 | Water insoluble polypeptides |
Publications (4)
Publication Number | Publication Date |
---|---|
FI884297A0 FI884297A0 (fi) | 1988-09-19 |
FI884297A FI884297A (fi) | 1989-03-22 |
FI96919B true FI96919B (fi) | 1996-06-14 |
FI96919C FI96919C (fi) | 1996-09-25 |
Family
ID=10624108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI884297A FI96919C (fi) | 1987-09-21 | 1988-09-19 | Veteen liukenemattomia polypeptidejä |
Country Status (23)
Country | Link |
---|---|
US (2) | US5192741A (fi) |
JP (1) | JPH0713023B2 (fi) |
AT (1) | AT397035B (fi) |
AU (1) | AU611944B2 (fi) |
BE (1) | BE1001685A5 (fi) |
CA (1) | CA1326438C (fi) |
CH (1) | CH675968A5 (fi) |
DE (2) | DE122004000023I2 (fi) |
DK (1) | DK175311B1 (fi) |
ES (1) | ES2009346A6 (fi) |
FI (1) | FI96919C (fi) |
FR (1) | FR2620621B1 (fi) |
GB (1) | GB2209937B (fi) |
GR (1) | GR1002244B (fi) |
IE (1) | IE60608B1 (fi) |
IL (1) | IL87790A (fi) |
IT (1) | IT1225148B (fi) |
LU (1) | LU87340A1 (fi) |
NL (1) | NL193818C (fi) |
NO (2) | NO178604C (fi) |
PT (1) | PT88557B (fi) |
SE (1) | SE503406C2 (fi) |
ZA (1) | ZA886827B (fi) |
Families Citing this family (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997815A (en) * | 1988-11-01 | 1991-03-05 | Children's Hospital Medical Center Of Northern California | Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin |
HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5225205A (en) * | 1989-07-28 | 1993-07-06 | Debiopharm S.A. | Pharmaceutical composition in the form of microparticles |
CH681425A5 (fi) * | 1990-11-14 | 1993-03-31 | Debio Rech Pharma Sa | |
CH679207A5 (fi) * | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
US5439688A (en) * | 1989-07-28 | 1995-08-08 | Debio Recherche Pharmaceutique S.A. | Process for preparing a pharmaceutical composition |
DE59003337D1 (de) * | 1989-10-16 | 1993-12-09 | Danubia Petrochem Polymere | Pressling mit retardierter Wirkstofffreisetzung. |
DE3935736A1 (de) * | 1989-10-27 | 1991-05-02 | Chemie Linz Deutschland | Pressling mit retardierter wirkstofffreisetzung |
CA2046830C (en) * | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
IT1243390B (it) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
YU48420B (sh) * | 1991-03-25 | 1998-07-10 | Hoechst Aktiengesellschaft | Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem |
CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
US5876452A (en) * | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
US6013853A (en) * | 1992-02-14 | 2000-01-11 | The University Of Texas System | Continuous release polymeric implant carrier |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
EP0630234B1 (en) * | 1992-03-12 | 1997-06-11 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
US5674534A (en) * | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5711968A (en) * | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US20030035845A1 (en) * | 1992-06-11 | 2003-02-20 | Zale Stephen E. | Composition for sustained release of non-aggregated erythropoietin |
US6514533B1 (en) | 1992-06-11 | 2003-02-04 | Alkermas Controlled Therapeutics, Inc. | Device for the sustained release of aggregation-stabilized, biologically active agent |
US5716644A (en) * | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
DE4223169C1 (de) * | 1992-07-10 | 1993-11-25 | Ferring Arzneimittel Gmbh | Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe |
FR2693905B1 (fr) * | 1992-07-27 | 1994-09-02 | Rhone Merieux | Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues. |
DK0674506T3 (da) * | 1992-12-02 | 2001-01-08 | Alkermes Inc | Væksthormonholdige mikrosfærer med styret frigivelse |
TW333456B (en) * | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
UA61046C2 (en) | 1992-12-07 | 2003-11-17 | Takeda Chemical Industries Ltd | Sustained-release preparation and method for its manufacture |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
CA2123144A1 (en) * | 1993-05-10 | 1994-11-11 | David Bodmer | Stabilisation of pharmacologically active compounds in sustained release compositions |
US5635216A (en) * | 1993-12-16 | 1997-06-03 | Eli Lilly And Company | Microparticle compositions containing peptides, and methods for the preparation thereof |
US6087324A (en) * | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
CA2178592C (en) * | 1993-12-09 | 2009-07-28 | Jurgen Engel | Long-acting injection suspensions and a process for their preparation |
DE4342092B4 (de) * | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
US5569468A (en) * | 1994-02-17 | 1996-10-29 | Modi; Pankaj | Vaccine delivery system for immunization, using biodegradable polymer microspheres |
US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
US20020193338A1 (en) * | 1994-02-18 | 2002-12-19 | Goldstein Steven A. | In vivo gene transfer methods for wound healing |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US6074840A (en) | 1994-02-18 | 2000-06-13 | The Regents Of The University Of Michigan | Recombinant production of latent TGF-beta binding protein-3 (LTBP-3) |
US5763416A (en) | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US5430021A (en) * | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
EP1125577B1 (en) * | 1994-04-08 | 2006-02-15 | QLT USA, Inc. | Liquid drug delivery compositions |
IE75744B1 (en) * | 1995-04-03 | 1997-09-24 | Elan Corp Plc | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
US5922253A (en) * | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
JP2000507912A (ja) * | 1995-08-31 | 2000-06-27 | アルカームズ コントロールド セラピューティックス,インコーポレイテッド | 作用剤の徐放性組成物 |
US5942253A (en) * | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
FR2748205A1 (fr) * | 1996-05-06 | 1997-11-07 | Debio Rech Pharma Sa | Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles |
US5817343A (en) | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
US5817627A (en) * | 1996-06-14 | 1998-10-06 | Theratechnologies Inc. | Long-acting galenical formulation for GRF peptides |
US5945128A (en) * | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US20070185032A1 (en) * | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
CA2275525C (en) * | 1996-12-20 | 2011-02-08 | Kevin J. Brodbeck | Gel composition and methods |
WO1998032423A1 (en) * | 1997-01-29 | 1998-07-30 | Takeda Chemical Industries, Ltd. | Sustained-release microspheres, their production and use |
CA2291659A1 (fr) * | 1997-06-04 | 1998-12-10 | Debio Recherche Pharmaceutique S.A. | Implants pour la liberation controlee de principes pharmaceutiquement actifs et procede pour leur fabrication |
US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
EP1007673B1 (en) | 1997-07-30 | 2008-12-17 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
US7128927B1 (en) | 1998-04-14 | 2006-10-31 | Qlt Usa, Inc. | Emulsions for in-situ delivery systems |
US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
IT1304152B1 (it) * | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
KR100321854B1 (ko) * | 1998-12-30 | 2002-08-28 | 동국제약 주식회사 | 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법 |
US7018654B2 (en) * | 1999-03-05 | 2006-03-28 | New River Pharmaceuticals Inc. | Pharmaceutical composition containing an active agent in an amino acid copolymer structure |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
JP2002539172A (ja) | 1999-03-17 | 2002-11-19 | ノバルティス アクチエンゲゼルシャフト | Tgf−ベータを含む医薬組成物 |
ES2169980B1 (es) | 1999-12-17 | 2003-11-01 | Lipotec Sa | Microcapsulas para la liberacion prolongada de farmacos. |
US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
US20030211974A1 (en) * | 2000-03-21 | 2003-11-13 | Brodbeck Kevin J. | Gel composition and methods |
US6362308B1 (en) * | 2000-08-10 | 2002-03-26 | Alkermes Controlled Therapeutics Inc. Ii | Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content |
DE60136002D1 (de) | 2000-10-06 | 2008-11-13 | Pacira Pharmaceuticals Inc | Parenteral verabreichbare mikropartikel-zubereitung mit kontrollierter freisetzung |
SE517421C2 (sv) | 2000-10-06 | 2002-06-04 | Bioglan Ab | Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav |
SE517422C2 (sv) | 2000-10-06 | 2002-06-04 | Bioglan Ab | Farmaceutiskt acceptabel stärkelse |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
SE518008C2 (sv) * | 2000-11-16 | 2002-08-13 | Bioglan Ab | Parenteralt administrerbara mikropartiklar och förfarande för framställning av desamma |
SE518007C2 (sv) | 2000-11-16 | 2002-08-13 | Bioglan Ab | Förfarande för framställning av mikropartiklar |
AU2002219198B2 (en) * | 2000-12-27 | 2006-06-29 | Ares Trading S.A. | Lipid microparticles by cryogenic micronization |
US20070142325A1 (en) * | 2001-01-08 | 2007-06-21 | Gustavsson Nils O | Starch |
WO2003000156A1 (en) | 2001-06-22 | 2003-01-03 | Southern Biosystems, Inc. | Zero-order prolonged release coaxial implants |
WO2003013609A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
US7105181B2 (en) * | 2001-10-05 | 2006-09-12 | Jagotec, Ag | Microparticles |
US20040043938A1 (en) * | 2001-11-06 | 2004-03-04 | Dinesh Purandare | Combination therapy for estrogen-dependent disorders |
SE0201599D0 (sv) * | 2002-03-21 | 2002-05-30 | Skyepharma Ab | Microparticles |
US20090035260A1 (en) * | 2002-07-29 | 2009-02-05 | Therapicon Srl | Enhanced nasal composition of active peptide |
US7658998B2 (en) * | 2003-01-22 | 2010-02-09 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
DE602004028678D1 (de) | 2003-01-28 | 2010-09-23 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur Behandlung von Magen-Darm-Störungen |
GB0304726D0 (en) * | 2003-03-01 | 2003-04-02 | Ardana Bioscience Ltd | New Process |
ATE510605T1 (de) * | 2003-03-14 | 2011-06-15 | Univ Columbia | Systeme und verfahren für auf blut basierende therapien mit einer membranlosen mikrofluid- austauschvorrichtung |
US20060076295A1 (en) | 2004-03-15 | 2006-04-13 | The Trustees Of Columbia University In The City Of New York | Systems and methods of blood-based therapies having a microfluidic membraneless exchange device |
EP1615959B1 (en) | 2003-04-10 | 2013-06-05 | Evonik Corporation | A method for the production of emulsion-based micro particles |
US20070207211A1 (en) * | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
US20050112087A1 (en) * | 2003-04-29 | 2005-05-26 | Musso Gary F. | Pharmaceutical formulations for sustained drug delivery |
US20060193825A1 (en) * | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
AU2004259208B2 (en) * | 2003-07-15 | 2011-04-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
EP2444069B1 (en) | 2003-07-23 | 2019-06-05 | Evonik Corporation | Controlled release compositions |
US6987111B2 (en) * | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
US7309232B2 (en) * | 2003-10-10 | 2007-12-18 | Dentigenix Inc. | Methods for treating dental conditions using tissue scaffolds |
CN105820160B (zh) | 2003-11-05 | 2019-02-12 | 萨可德生物科学公司 | 细胞粘着调节剂 |
ITMI20040235A1 (it) * | 2004-02-13 | 2004-05-13 | Therapicon Srl | Preparazione farmaceutica per il cavo orale |
CN103920162B (zh) * | 2004-04-23 | 2017-07-11 | 安姆根有限公司 | 持续释放制剂 |
GB0412866D0 (en) * | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
CA2575988C (en) | 2004-08-04 | 2014-02-18 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
ES2255426B1 (es) | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
EP1674082A1 (de) | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
ES2363364T3 (es) * | 2005-01-05 | 2011-08-02 | Eli Lilly And Company | Dihidrato de pamoato de olanzapina. |
US9649382B2 (en) | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
US8871712B2 (en) * | 2005-01-14 | 2014-10-28 | Camurus Ab | Somatostatin analogue formulations |
ATE462409T1 (de) | 2005-01-14 | 2010-04-15 | Camurus Ab | Topische bioadhäsive formulierungen |
US9060935B2 (en) * | 2005-01-21 | 2015-06-23 | Camurus Ab | Pharmaceutical lipid compositions |
CA2596357A1 (en) * | 2005-02-01 | 2006-08-10 | Attenuon, Llc | Acid addition salts of ac-phscn-nh2 |
AU2006241072A1 (en) * | 2005-04-25 | 2006-11-02 | Amgen Inc. | Biodegradable peptide sustained release compositions containing porogens |
PL2444079T3 (pl) | 2005-05-17 | 2017-07-31 | Sarcode Bioscience Inc. | Kompozycje i sposoby leczenia chorób oczu |
JP5198261B2 (ja) * | 2005-06-06 | 2013-05-15 | カムルス エービー | Glp−1類似体製剤 |
CN101258163B (zh) * | 2005-06-30 | 2013-08-21 | 益普生制药股份有限公司 | Glp-1药物组合物 |
US20070106271A1 (en) * | 2005-11-09 | 2007-05-10 | Searete Llc, A Limited Liability Corporation | Remote control of substance delivery system |
KR100722607B1 (ko) * | 2006-05-11 | 2007-05-28 | 주식회사 펩트론 | 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법 |
US7403325B2 (en) * | 2006-05-19 | 2008-07-22 | Xerox Corporation | Electrophoretic display device |
CN101534917A (zh) * | 2006-05-22 | 2009-09-16 | 纽约市哥伦比亚大学理事会 | 采用萃取流体排出流过滤的微流无膜交换***和方法 |
US20080075777A1 (en) * | 2006-07-31 | 2008-03-27 | Kennedy Michael T | Apparatus and methods for preparing solid particles |
US7858663B1 (en) | 2007-10-31 | 2010-12-28 | Pisgah Laboratories, Inc. | Physical and chemical properties of thyroid hormone organic acid addition salts |
US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
US20080293695A1 (en) * | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
US8211905B1 (en) | 2007-05-22 | 2012-07-03 | Pisgah Laboratories, Inc. | Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties |
US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
US9421266B2 (en) | 2007-05-22 | 2016-08-23 | Pisgah Laboratories, Inc. | Safety of pseudoephedrine drug products |
US8329720B1 (en) | 2007-05-22 | 2012-12-11 | Pisgah Laboratories, Inc. | Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties |
US10183001B1 (en) | 2007-05-22 | 2019-01-22 | Pisgah Laboratories, Inc. | Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US10166181B2 (en) * | 2007-06-06 | 2019-01-01 | Debiopharm Research & Manufacturing Sa | Slow release pharmaceutical composition made of microgranules |
GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
EP3797775A1 (en) | 2007-10-19 | 2021-03-31 | Novartis AG | Compositions and methods for treatment of diabetic retinopathy |
CA2709712C (en) | 2007-12-20 | 2016-05-10 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles having a low residual solvent volume |
AU2009212396A1 (en) * | 2008-02-04 | 2009-08-13 | The Trustees Of Columbia University In The City Of New York | Fluid separation devices, systems and methods |
US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
CN102065893A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | Lfa-1拮抗剂向胃肠***的递送 |
US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
BRPI0916557A2 (pt) | 2008-07-30 | 2020-08-04 | Mesynthes Limited | arcabouços de tecido derivado da matriz extracelular do pré-estômago |
GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
WO2010025435A2 (en) | 2008-08-29 | 2010-03-04 | Genzyme Corporation | Controlled-released peptide formulations |
US20100062057A1 (en) * | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
WO2010119319A1 (en) | 2009-03-09 | 2010-10-21 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof |
US20110091518A1 (en) * | 2009-09-22 | 2011-04-21 | Danielle Biggs | Implant devices having varying bioactive agent loading configurations |
US8378105B2 (en) * | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
ES2363964B1 (es) | 2009-11-20 | 2012-08-22 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados. |
ES2363965B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm S.A. | Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados. |
CN102665698A (zh) | 2009-12-23 | 2012-09-12 | 迪菲安特制药有限责任公司 | 可用于治疗心血管疾病的联合组合物 |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
EP2398488B1 (en) * | 2010-01-04 | 2018-11-14 | Mapi Pharma Limited | Depot system comprising glatiramer acetate |
ES2383271B1 (es) | 2010-03-24 | 2013-08-01 | Lipotec S.A. | Procedimiento de tratamiento de fibras y/o materiales textiles |
ES2385240B1 (es) | 2010-07-26 | 2013-09-23 | Gp-Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
MX362218B (es) | 2011-05-04 | 2019-01-09 | Balance Therapeutics Inc | Derivados de pentilentetrazol. |
WO2013072767A1 (en) | 2011-11-18 | 2013-05-23 | Pronova Biopharma Norge As | Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
WO2013150384A1 (en) | 2012-04-04 | 2013-10-10 | Pronova Biopharma Norge As | Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof |
ES2606392T3 (es) | 2012-04-04 | 2017-03-23 | Pronova Biopharma Norge As | Composiciones que comprenden ácidos grasos omega-3 y vitamina D para acné vulgar y/o eccema, y procedimientos y usos de las mismas |
IN2014DN09621A (fi) * | 2012-05-14 | 2015-07-31 | Teijin Ltd | |
EA035495B1 (ru) | 2012-05-25 | 2020-06-25 | Камурус Аб | Состав-предшественник, содержащий агонист рецепторов соматостатина, способ лечения путем его введения, его применение, предварительно заполненное устройство, содержащее его, и набор, содержащий указанное устройство |
CN110922393A (zh) | 2012-07-25 | 2020-03-27 | 诺华股份有限公司 | Lfa-1抑制剂及其多晶型物 |
CA2902348C (en) | 2013-02-25 | 2021-11-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
AU2014222389B2 (en) | 2013-02-28 | 2018-11-29 | Pronova Biopharma Norge As | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
FR3002735B1 (fr) * | 2013-03-04 | 2015-07-03 | Virbac | Composition orale nutritionnelle et medicamenteuse a usage veterinaire |
FR3002736B1 (fr) | 2013-03-04 | 2015-06-26 | Virbac | Composition orale nutritionnelle et medicamenteuse a usage veterinaire |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
EP3054969B1 (en) | 2013-10-10 | 2021-03-10 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
US10046058B2 (en) * | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US20190002356A1 (en) | 2015-07-15 | 2019-01-03 | Neha Yeshwanta HEBALKAR | Improved process for producing silica aerogel thermal insulation product with increased efficiency |
US10653744B2 (en) | 2016-01-11 | 2020-05-19 | Bausch Health Ireland Limited | Formulations and methods for treating ulcerative colitis |
CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
CA3077011A1 (en) | 2017-09-26 | 2019-04-04 | Nanomi B.V. | Method for preparing micro-particles by double emulsion technique |
CN110123658B (zh) * | 2019-05-22 | 2022-07-15 | 上海璞萃生物科技有限公司 | 一种具有自组装聚集体结构的超分子多肽及其制备方法 |
IT202000017191A1 (it) | 2020-07-15 | 2022-01-15 | Xbrane Biopharma Ab | Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale |
CN116803378B (zh) * | 2023-08-24 | 2023-11-17 | 北京福元医药股份有限公司 | 一种格列齐特缓释片剂及其制备方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4010125A (en) * | 1975-06-12 | 1977-03-01 | Schally Andrew Victor | [D-Trp6 ]-LH-RH and intermediates therefor |
US4622244A (en) * | 1979-09-04 | 1986-11-11 | The Washington University | Process for preparation of microcapsules |
US4293539A (en) * | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
US4341767A (en) * | 1980-10-06 | 1982-07-27 | Syntex Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
PH19942A (en) * | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3378250D1 (en) * | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
US4667014A (en) * | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
CH660488A5 (en) * | 1982-12-17 | 1987-04-30 | Sandoz Ag | (Co)oligomeric hydroxycarboxylic acid derivatives, the preparation thereof, and the use thereof in pharmaceutical compositions |
CH661206A5 (fr) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes. |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4547370A (en) * | 1983-11-29 | 1985-10-15 | The Salk Institute For Biological Studies | GnRH Antagonists |
US4708861A (en) * | 1984-02-15 | 1987-11-24 | The Liposome Company, Inc. | Liposome-gel compositions |
US4632979A (en) * | 1984-06-18 | 1986-12-30 | Tulane Educational Fund | Therapeutic LHRH analogs |
GB8416234D0 (en) * | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
US4647653A (en) * | 1984-08-23 | 1987-03-03 | Tulane Educational Fund | Therapeutic peptides |
ZA855567B (en) * | 1984-08-31 | 1986-03-26 | Salk Inst For Biological Studi | Insulin-selective somatostatin analogs |
CH660302A5 (fr) * | 1984-10-17 | 1987-04-15 | Debiopharm Sa | Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles. |
JPS61172813A (ja) * | 1985-01-28 | 1986-08-04 | Japan Atom Energy Res Inst | ポリ乳酸を担体とする徐放性複合体の製造方法 |
DE3678308D1 (de) * | 1985-02-07 | 1991-05-02 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von mikrokapseln. |
US4677193A (en) * | 1985-02-22 | 1987-06-30 | The Salk Institute For Biological Studies | Peptides containing an aliphatic-aromatic ketone side chain |
US4666704A (en) * | 1985-05-24 | 1987-05-19 | International Minerals & Chemical Corp. | Controlled release delivery system for macromolecules |
IL79134A (en) * | 1985-07-29 | 1991-06-10 | American Cyanamid Co | Continuous release peptide implants for parenteral administration |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US5089471A (en) * | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
DE3734223A1 (de) * | 1987-10-09 | 1989-04-20 | Boehringer Ingelheim Kg | Implantierbares, biologisch abbaubares wirkstofffreigabesystem |
CA2012901A1 (en) * | 1989-04-05 | 1990-10-05 | Quirico Branca | Amino acid derivatives |
-
1987
- 1987-09-21 GB GB8722134A patent/GB2209937B/en not_active Expired - Lifetime
-
1988
- 1988-07-04 DE DE122004000023C patent/DE122004000023I2/de active Active
- 1988-07-04 DE DE3822459A patent/DE3822459C2/de not_active Expired - Lifetime
- 1988-09-08 IE IE272788A patent/IE60608B1/en not_active IP Right Cessation
- 1988-09-12 AT AT0223488A patent/AT397035B/de not_active IP Right Cessation
- 1988-09-13 ZA ZA886827A patent/ZA886827B/xx unknown
- 1988-09-13 CA CA000577205A patent/CA1326438C/en not_active Expired - Lifetime
- 1988-09-14 FR FR8811991A patent/FR2620621B1/fr not_active Expired - Lifetime
- 1988-09-16 DK DK198805189A patent/DK175311B1/da active Protection Beyond IP Right Term
- 1988-09-16 ES ES8802838A patent/ES2009346A6/es not_active Expired
- 1988-09-16 AU AU22326/88A patent/AU611944B2/en not_active Expired
- 1988-09-16 GR GR880100619A patent/GR1002244B/el not_active IP Right Cessation
- 1988-09-19 IL IL87790A patent/IL87790A/xx active Protection Beyond IP Right Term
- 1988-09-19 NO NO884154A patent/NO178604C/no not_active IP Right Cessation
- 1988-09-19 FI FI884297A patent/FI96919C/fi not_active IP Right Cessation
- 1988-09-20 CH CH3494/88A patent/CH675968A5/fr not_active IP Right Cessation
- 1988-09-20 IT IT8805213A patent/IT1225148B/it active
- 1988-09-20 PT PT88557A patent/PT88557B/pt not_active IP Right Cessation
- 1988-09-20 SE SE8803321A patent/SE503406C2/sv not_active IP Right Cessation
- 1988-09-20 US US07/247,060 patent/US5192741A/en not_active Expired - Lifetime
- 1988-09-20 BE BE8801079A patent/BE1001685A5/fr not_active IP Right Cessation
- 1988-09-20 NL NL8802323A patent/NL193818C/nl not_active IP Right Cessation
- 1988-09-21 LU LU87340A patent/LU87340A1/fr unknown
- 1988-09-21 JP JP63238626A patent/JPH0713023B2/ja not_active Expired - Lifetime
-
1994
- 1994-02-10 US US08/196,872 patent/US5776885A/en not_active Expired - Lifetime
-
2005
- 2005-05-03 NO NO20050012C patent/NO2005012I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI96919B (fi) | Veteen liukenemattomia polypeptidejä | |
US6399103B1 (en) | Method of producing a sustained-release preparation | |
CN101035512B (zh) | 用于生物活性化合物可控制释放递送的药物组合物 | |
AU670168B2 (en) | Controlled release growth hormone containing microspheres | |
US5639480A (en) | Sustained release formulations of water soluble peptides | |
US8637077B2 (en) | Sustained-release preparation | |
IE902435A1 (en) | Processes for the preparation of sustained release formulations of water soluble peptides | |
US5395916A (en) | Biodegradable copolymer from hydroxy proline | |
JP2702729B2 (ja) | 徐放性埋込剤 | |
Anik et al. | Delivery systems for LHRH and analogs | |
US5212154A (en) | Preparation for treating complications in diabetes | |
NL195089C (nl) | Preparaten van in water oplosbare peptiden met een langzame afgifte. | |
NERENBERG et al. | ST ANIK, LM SANDERS, MD CHAPLIN, S. KUSHINSKY and |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB | Publication of examined application | ||
PC | Transfer of assignment of patent |
Owner name: DEBIO RECHERCHE PHARMACEUTIQUE SA |
|
FG | Patent granted |
Owner name: DEBIO RECHERCHE PHARMACEUTIQUE S.A. |
|
SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20050009 |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: L204 Extension date: 20130918 |
|
MA | Patent expired |